Aster DM Healthcare Share: Q4 Mein Dhamaka, Merger Ke Baad Bhaaga Share! Lekin Valuation Ka Chakkar Kya Hai?

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAarav Shah|Published at:
Aster DM Healthcare Share: Q4 Mein Dhamaka, Merger Ke Baad Bhaaga Share! Lekin Valuation Ka Chakkar Kya Hai?
Overview

Aster DM Healthcare ke investors ke liye aaj ka din zabardast raha! Company ne Q4 mein **77%** ka record profit growth dikhaya, Rs **1.4 billion** kamaya. Revenue bhi **18%** badh ke Rs **11.8 billion** ho gaya. Aur is sabke beech, Quality Care India Ltd ke saath merger bhi almost final ho gaya hai!

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Q4 Results Aur Merger Ka Dhamaka

Toh bhai, yeh 77% ka profit jump Rs 1.4 billion tak pahuncha, aur revenue bhi Rs 11.8 billion ho gaya. EBITDA margins bhi mast 19.65% tak pahunch gaye. Sabse badi baat, Quality Care India Ltd (QCIL) ke saath merger bhi nearly 96.68% shareholder approval ke saath almost complete hone wala hai. India mein ek bada healthcare player banne wala hai yeh combo, jismein 10,600+ beds honge!

Valuation Mein Gap? Brokeurs Kya Bolte Hain?

Abhi Indian healthcare sector bhi full speed mein hai, next few years mein 16-18% growth expected hai. Aster DM is merger se position strong kar raha hai. Lekin bhai, valuation ka thoda chakkar hai. Aster DM ka current P/E ratio 110-120 ke aas paas hai, jo competitors se kaafi zyada hai. Jaise Apollo Hospitals ka approx 60, Max Healthcare ka 68, aur Fortis Healthcare ka 72. Iska matlab hai ki market future growth pakad raha hai ya valuation thoda over the top lag raha hai.

Risks Aur Challenges Ko Mat Bhoolna!

Itna sab acha hone ke baad bhi, bhai, kuch cheezein hain jo dhyan rakhne wali hain. Itne bade merged entity ko manage karna, synergies extract karna, yeh sab mein execution risks hote hain. Aur sector mein waise bhi challenges hain - healthcare access, skilled staff ki kami, patients ka out-of-pocket expense, jo demand ko indirectly affect kar sakte hain. Analysts ke price targets bhi pehle Rs 510-580 the, phir Rs 700-850 ho gaye, toh thoda volatile hai forecasting karna.

Analysts Ka Bharosa Aur Future Projections

Par overall, analyst logon ka view positive hai. 10 analysts ne 'Strong Buy' rating di hai. Average 12-month target Rs 717.10 hai, high estimate Rs 860 tak jaa rahi hai. Prabhudas Lilladher ne toh Rs 800 ka target diya hai, jo FY28 earnings ka 30x EV/EBITDA multiple pakad raha hai. Iska matlab hai ki future mein earnings growth kaafi zyada expect kar rahe hain. Company khud bhi expect kar rahi hai ki merged entity ka EBITDA FY26-28 mein 22% CAGR se badhega, aur FY28 tak Rs 29 billion ho jayega. Ab sab kuch successful execution par depend karta hai!

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.